Detailed demographics and clinical characteristics of the patients in both groups that were examined in this study
| Parameter | pSpA (n=30) | non-SpA (n=30) | P value |
| Male gender (%) | 53.3 | 20.0 | 0.008 |
| Age (years, mean±SD) | 37.5±5.9 | 36.9±7.7 | 0.694 |
| CRP (mg/dL) mean±SD | 0.54±0.9 | 0.58±0.9 | 0.473 |
| ESR (mm/1 hour, mean±SD) | 15.2±18.4 | 14.9±11.5 | 0.486 |
| HLA-B27 positive (%) | 66.7% | 13.3% | 0.001 |
| Symptom duration (months) | 17.2±27.5 | 4.4±4.3 | 0.005 |
| PatGA (0–10, mean±SD) | 5.6±1.6 | 6.5±2.5 | 0.066 |
| PhysGA (0–10, mean±SD) | 5.2±1.4 | 6.1±2.2 | 0.099 |
| BASDAI (0–10, mean±SD) | 5.3±2.9 | – | – |
| ASDAS (mean±SD) | 2.1±ß.7 | – | – |
| BASFI (0–10, mean±SD) | 4.7±2.3 | – | – |
| ASQoL (mean±SD) | 9.9±5.2 | – | – |
| NSAIDs intake (% patients) | 66.7 | 56.7 | 0.430 |
| NSAID index (mean±SD) | 37.0±42.2 | 22.4±30.6 | 0.161 |
| Steroids intake (% patients) | 23.3 | 26.7 | 0.767 |
| DMARDs intake (% patients) | 16.7 | 33.3 | 0.139 |
| Biologics intake (% patients) | 20.0 | 13.3 | 0.492 |
ASDAS, Ankylosing Spondylitis Disease Activity Score; ASQoL, Ankylosing Spondylitis Quality of Life Questionnaire; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Function Index; CRP, C reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HLA, human leucocyte antigen; non-SpA, other diagnoses than spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PatGA, patients’ global assessment; PhysGA, physicians’ global assessment; pSpA, peripheral spondyloarthritis.